{
    "eid": "2-s2.0-85065336477",
    "title": "The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism",
    "cover-date": "2019-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Critical Care and Intensive Care Medicine",
            "@code": "2706",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Nephrology",
            "@code": "2727",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "chronic hemodialysis",
        "Cinacalcet",
        "severe secondary hyperparathyroidism"
    ],
    "authors": [
        "Paweena Susantitaphong",
        "Somratai Vadcharavivad",
        "Teerada Susomboon",
        "Wanchana Singhan",
        "Netsiri Dumrongpisutikul",
        "Ketsuda Jakchairoongruang",
        "Somchai Eiam-Ong",
        "Kearkiat Praditpornsilpa"
    ],
    "citedby-count": 14,
    "ref-count": 37,
    "ref-list": [
        "KDIGO clinical practice guideline for the diagnosis. Evaluation, prevention, and treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD\u2013MBD)",
        "Induction of cardiac FGF-23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease",
        "Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease",
        "The future of phosphate binders: a perspective on novel therapeutics",
        "Association between hemodialysis patient outcomes and compliance with KDOQI and KDIGO targets for mineral and bone metabolism",
        "Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving Global Outcomes 2017 Clinical Practice Guideline Update",
        "Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder",
        "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease",
        "Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl",
        "The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism",
        "Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials",
        "Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis",
        "Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials",
        "Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism",
        "Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study",
        "Chronic kidney disease-mineral-bone disorder: a new paradigm",
        "Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy",
        "Vascular calcification and renal osteodystrophy relationship in chronic kidney disease",
        "Pathogenesis of refractory hyperparathyroidism",
        "Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism",
        "Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients",
        "Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism",
        "The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism",
        "Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosis",
        "Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease",
        "Surgical treatment of renal hyperparathyroidism",
        "Parathyroid function in persistent hyperparathyroidism: relationship to gland size",
        "Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design",
        "Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism",
        "Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism",
        "Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism",
        "FGF23 induces left ventricular hypertrophy",
        "Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study",
        "Surgical management of secondary hyperparathyroidism in chronic kidney disease-a consensus report of the European Society of Endocrine Surgeons",
        "Changes in serum concentrations of fibroblast growth factor 23 and soluble klotho in hemodialysis patients after total parathyroidectomy",
        "Impact of parathyroidectomy on serum FGF-23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism",
        "Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD)\u2013a systematic review and meta-analysis"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn University",
        "Kyowa Hakko Kirin"
    ]
}